DDD
6 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (NCT05067127) | Apellis Pharmaceuticals, Inc. | 2021-11-12 |
| The PerX360º System™ Registry (NCT01796535) | Interventional Spine, Inc. | 2012-11-01 |
| MaxAn Post Market Surveillance Validation (NCT01343693) | Zimmer Biomet | 2011-06-01 |
| C3G/Primary IC-MPGN EAP (NCT04729062) | Apellis Pharmaceuticals, Inc. |
Track DDD automatically
Every clearance here is in the API, with alerts when new ones post.